At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Everolimus +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas
In Brief
A Phase 2 clinical trial evaluating Everolimus, Laboratory Biomarker Analysis, and 1 other intervention for Ovarian Endometrioid Adenocarcinoma and 8 related conditions. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
This pilot, phase II trial studies how well everolimus and letrozole work in treating patients with hormone receptor positive ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back. Everolimus and letrozole may stop the growth of tumor cells by blocking some the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartNov 2014
Primary CompletionJun 2016
Study CompletionJun 2018
TodayJul 2026
First PostedNov 5, 2014
Enrollment StartNov 14, 2014
Primary CompletionJun 15, 2016
Study CompletionJun 21, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.7 years ago
Interventions
Everolimusdrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Letrozoledrug
Given PO